Phesi Publishes Digital Patient Profile Catalog
Profiles are based on data from more than 60 million patients, with aim to enable adoption of digital twins and improve patient centricity in drug development.
Phesi, a global provider of patient-centric data software and services, has published the first edition of its Digital Patient Profile (DPP) catalog to deliver granular patient-level data for 28 key disease indications. The profiles, based on 485,000 curated clinical trials and amendments, and data from more than 60 million patients, provide a statistical view of patient attributes for 11 oncology indications and other prevalent diseases including Alzheimer’s, COVID-19, Crohn’s disease and ulcerative colitis. The profiles will be used by sponsors to improve program and trial protocol design, and enable the industry to develop Digital Twins and Digital Trial Arms as part of clinical development strategies. DPPs will also support wider adoption of single arm trials by helping sponsors demonstrate efficacy and safety in relevant patient cohorts.
Dr. Gen Li, Founder and President, Phesi, said in a press release, “What we know about the global patient population has evolved significantly as medicine has advanced, along with other socioeconomic changes. Sponsors must use the data gathered from historical and existing trials and clinical research to move from “perception led” to “data led” program and study design.”
Reference: Phesi publishes first edition of Digital Patient Profile Catalog to enable adoption of Digital Twins and improve patient centricity in drug development. Boston, USA, May 3, 2023.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
